Toleranzia’s tolerogens are highly flexible – the disease-specific proteins may be adapted to a variety of autoimmune diseases.

Toleranzia focuses on autoimmune orphan diseases with great medical need and great market potential.

Toleranzia’s main focus is the autoimmune orphan disease myasthenia gravis, for which the company is developing the drug candidate TOL2.

Toleranzia recently established another indication in autoimmune orphan diseases; ANCA vasculitis, for which the company develops the drug candidate TOL3.